Moreover, we assessed the association of TILs in metastatic tissue and survival outcomes, including progression-free survival (PFS) and melanoma-specific survival (MSS) after first-line anti-PD-1-based therapy and targeted therapy with BRAF and MEK inhibitors. Here, BRAF is linked to melanoma.